This move is archived. Current quotes and coverage live on the stock page.
Follow FRX
Fennec Pharmaceuticals Inc experienced a notable drop in its stock price during yesterday's trading session.
Fennec Pharmaceuticals Inc (FRX.TO) saw its stock decline by 3.70% yesterday, closing at CA$16.38. This downturn reflects ongoing challenges in the biotech sector, which has been under pressure as investors reassess growth prospects amid a shifting market landscape.
Advertisement
Fennec Pharmaceuticals Inc
FRX.TO
FRX.TO
Fennec Pharmaceuticals Inc
WealthAwesomeMarket cap
$521.10M
52W high
$17.64
52W low
$7.59
1W change
+0.27%
Beta
1.23
Analyst Price Targets
Based on analyst covering FRX · as of Sep 17, 2026
Wall Street analysts forecast FRX stock price to rise 529.7% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$93.57
+529.7% Upside
Current Price
C$14.86
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on FRX's historical volatility
30-Day Vol
59.4%
Annualized
90-Day Vol
58.2%
Annualized
Trend (90d)
-12.8%
Annualized drift
90d Mean
C$14.20
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$14.64 | C$11.92 – C$17.97 |
| 60 trading days | C$14.41 | C$10.79 – C$19.26 |
| 90 trading days | C$14.20 | C$9.95 – C$20.25 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should remain cautious with Fennec Pharmaceuticals, as the recent decline highlights potential vulnerabilities in its market performance and investor sentiment.
Fennec Pharmaceuticals Inc down 3.70%
The company’s market cap stands at CA$596 million, reflecting a significant valuation adjustment following yesterday's trading session.
Bull case
Fennec has a promising product pipeline, especially with PEDMARK®. If market conditions improve, this product could drive future growth for the company.
Bear case
The recent stock performance raises concerns about Fennec's ability to maintain investor confidence and achieve sustainable profitability.
Market Reaction
Advertisement
The 3.70% drop in Fennec Pharmaceuticals' stock price yesterday reflects broader market trends affecting biotech companies. Investors are increasingly cautious, leading to a reevaluation of growth expectations.
Company Performance
Despite the decline, Fennec Pharmaceuticals has shown resilience in its product development. However, the recent stock performance raises questions about its ability to attract and retain investor interest amidst competitive pressures.
Looking Ahead
As Fennec Pharmaceuticals continues to navigate the complexities of the biotech landscape, investors should monitor upcoming announcements and market conditions closely. For more insights, check out our detailed analysis on Fennec Pharmaceuticals Inc.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
